Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 7/20 | 0.60 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | ADRB3 | P13945 | 9/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4867710 | 1.00 | ADRB2 (0.60) | ADRB2NAMPTADRB3KDM4EGAA | |
| SCHEMBL6619401 | 0.83 | ADRB2 (0.72) | ADRB2ADRB3KDM4EGAASMN1; SMN2 | |
| SCHEMBL4867801 | 0.82 | NAMPT (0.58) | NAMPTGAACTSKCA1CA2 | |
| SCHEMBL27916601 | 0.82 | ADRB3 (0.62) | ADRB2ADRB3KDM4EGAASMN1; SMN2 | |
| SCHEMBL17209085 | 0.82 | ADRB3 (0.62) | ADRB2ADRB3KDM4EGAASMN1; SMN2 | |
| SCHEMBL1624911 | 0.80 | NPC1 (0.58) | KDM4ESMN1; SMN2CTSK | |
| SCHEMBL7739354 | 0.80 | NPC1 (0.58) | KDM4ESMN1; SMN2CTSK | |
| SCHEMBL350453 | 0.80 | NPC1 (0.58) | KDM4ESMN1; SMN2CTSK | |
| SCHEMBL572740 | 0.80 | IDO1 (0.60) | NAMPTGAACTSKCA1CA2 | |
| SCHEMBL23291264 | 0.79 | NAMPT (0.57) | NAMPTSMN1; SMN2TDP1CTSKCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-10-30 | — | — | US | disclosed |
| US-7427639-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-08-02 | — | — | US | disclosed |
| US-7217738-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7211695-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-7105701-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-20060183918-A1 | Beta 2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2006-08-17 | — | — | US | disclosed |
| EP-1019075-B9 | BETA 2-ADRENERGIC RECEPTOR AGONISTS | THERAVANCE INC (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20050261338-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-11-24 | — | — | US | disclosed |
| US-20050209275-A1 | Beta 2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-09-22 | — | — | US | disclosed |
| EP-1235787-A1 | $g(b)2-ADRENERGIC RECEPTOR AGONISTS | Theravance, Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
| US-20020055651-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2002-05-09 | — | — | US | disclosed |
| WO-2001042193-A1 | β2-ADRENERGIC RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
| EP-1082289-A4 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | ADVANCED MEDICINE INC (US) | 2001-03-14 | — | — | EP | disclosed |
| EP-1082289-A1 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | Advanced Medicine, Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| EP-1019075-A4 | $g(b)2-ADRENERGIC RECEPTOR AGONISTS | ADVANCED MEDICINE INC (US) | 2000-12-13 | — | — | EP | disclosed |
| WO-1999066944-A9 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | ADVANCED MEDICINE INC (US) | 2000-07-27 | — | — | WO | disclosed |
| EP-1019075-A1 | $g(b)2-ADRENERGIC RECEPTOR AGONISTS | Advanced Medicine, Inc. (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999066944-A1 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999064035-A1 | β2-ADRENERGIC RECEPTOR AGONISTS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261338-A1 | Beta2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885NAMPT 3474/4885ADRB3 4/4885 |
| US-20020055651-A1 | Beta2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885NAMPT 3399/4885ADRB3 4/4885 |
| US-20050209275-A1 | Beta 2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885NAMPT 3589/4885ADRB3 4/4885 |
| US-20060183918-A1 | Beta 2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885NAMPT 3589/4885ADRB3 4/4885 |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885NAMPT 3474/4885ADRB3 4/4885 |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885NAMPT 3474/4885ADRB3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.